Sujana Movva, MD
- Request Appointment
- Clinical Locations
- Education, Training & Credentials
- Patient Stories
- Research Profile
Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111
Assistant Professor, Department of Hematology/Oncology
Sarcoma & Melanoma
I decided to join Fox Chase Cancer Center because of the expertise in the field of sarcoma and the institution’s dedication to cancer care. I continue to be impressed by the passion toward this mission exhibited by every employee here.
Patients with sarcomas are usually otherwise healthy and young; therefore, I think that it is of utmost importance to find new drugs for this disease. My interest in clinical research includes finding new agents for patients with sarcoma and melanoma and trying to figure out why certain patients respond to treatments and others do not.
A cancer diagnosis is a life changing event. I think it is important for patients to feel confident in the care they are receiving. I hope that my patients always feel that they are important and that the relationship allows them to maintain hope and control during this time in their life.
- Fellow, Hematology Oncology, University of New Mexico, Albuquerque, NM, 2007-2010
- Resident, Internal Medicine, Michigan State University, Mclaren Regional Medical Center, Flint, MI, 2004-2007
- MD, University of Western Ontario, London, Canada, 2003
- American Board of Internal Medicine
- Board Certified in Medical Oncology
- National Comprehensive Cancer Network (NCCN)
- Bone Cancer Panel
- American Society of Clinical Oncology
- Connective Tissue Oncology Society
In early 2013, Victoria Mirarchi, who was very active and healthy at the age of 81, underwent a surgical procedure at her local hospital to remove a very large mass from her abdominal area. The pathology confirmed a diagnosis of liposarcoma. The tumor was aggressive and returned the following year. In mid-2014 Victoria was admitted to the hospital for another procedure, which was followed by 7 weeks of radiation therapy.
Sister Marcille McEntee is no stranger to miracles. As a Sister, and Servant of the Immaculate Heart of Mary, her faith is deep and abiding. Yet to see a miracle at work in her own life is still a special blessing.
At 6’4” inches tall and a trim 208 pounds, Abu-Methuselah Bradley was the epitome of good health. An athlete with a muscular build, this pharmaceutical sales representative and part-time church pastor enjoyed bike-riding, running and other outdoor activities. In September, 2013, at the age of 39, this married father of two noticed blood in his urine and took quick action. “I went right to the ER,” said Abu. “They ran some tests but couldn’t really tell me what was wrong.”
Just as Carla Rake’s children were starting school in September 2013, she learned her world was turning upside down. That summer, while her daughter, Kayla, 9, and son, Jalen, 12, were watching television, Carla overheard a commercial about the importance of watching your moles, especially if they were changing. “I had a mole on my abdomen forever, but hearing this commercial over and over, made me think it was time to have it checked,” recalls Carla, who made an appointment with a dermatologist.
Drug development, Biomarkers, Sarcoma
Norberg SM, Movva S. Role of genetic and molecular profiling in sarcomas. Curr Treat Options Oncol. 2015 May;16(5):339. doi: 10.1007/s11864-015-0339-3. PubMed
Movva S, Wen W, Chen W, Millis SZ, Gatalica Z, Reddy S, von Mehren M, Van Tine BA. Multi-platform profiling of over 2000 sarcomas: Identification of biomarkers and novel therapeutic targets. Oncotarget. 2015 Mar 26. [Epub ahead of print] PubMed
Verschraegen CF, Movva S, Ji Y, Schmit B, Quinn RH, Liem B, Bocklage T, Shaheen M. A phase I study of the combination of temsirolimus with irinotecan for metastatic sarcoma. Cancers (Basel). 2013 Apr 11;5(2):418-29. doi: 10.3390/cancers5020418. PubMed PMID: 24216984; PubMed Central PMCID: PMC3730334.
Cardona K, Movva S. Issues in the management of high-risk localized sarcomas. Curr Probl Cancer. 2013 Mar-Apr;37(2):62-73. doi: 10.1016/j.currproblcancer.2013.03.002. PubMed PMID: 23719331.
Cardona K, Williams R, Movva S. Multimodality therapy for advanced or metastatic sarcoma. Curr Probl Cancer. 2013 Mar-Apr;37(2):74-86. doi: 10.1016/j.currproblcancer.2013.03.003. Review. PubMed PMID: 23719332.
Movva S. Emerging therapies for sarcoma. Curr Probl Cancer. 2013 Mar-Apr;37(2):87-101. doi: 10.1016/j.currproblcancer.2013.03.004. Review. PubMed PMID: 23719333.
Verschraegen CF, Arias-Pulido H, Lee SJ, Movva S, Cerilli LA, Eberhardt S, Schmit B, Quinn R, Muller CY, Rabinowitz I, Purdy M, Snyder D, Bocklage T. Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen. Ann Oncol. 2012 Mar;23(3):785-90. doi: 10.1093/annonc/mdr299. Epub 2011 Jul 11. PubMed PMID: 21746804.
Movva S, Verschraegen C. Systemic management strategies for metastatic soft tissue sarcoma. Drugs. 2011 Nov 12;71(16):2115-29. doi: 10.2165/11594500-000000000-00000. Review. PubMed PMID: 22035513.
Movva S, Verschraegen CF, Rabinowitz I, Mangalik A, Parks V, Lee FC. Phase I dose finding study of carboplatin, paclitaxel, and temozolomide in advanced solid tumors. Melanoma Res. 2011 Feb;21(1):76-9. doi: 10.1097/CMR.0b013e32833d3293. PubMed PMID: 21169871.
Movva S, Verschraegen C. The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab (MDX-010), a novel treatment strategy in cancer management. Expert Opin Biol Ther. 2009 Feb;9(2):231-41. doi: 10.1517/14712590802643347 . Review. PubMed PMID: 19236253.
Movva S, von Mehren M, Ross EA, Handorf E. Patterns of chemotherapy administration in high risk soft tissue sarcoma and impact on overall survival. (JNCCN) Journal of the National Comprehensive Cancer Network, Vol. 13, Number 11, November, 2015.